Targeting KRAS mutations has been challenging due to the nature of the KRAS protein and its location inside the cell. However, recent advancements have led to the development of KRAS inhibitors such as sotorasib and adagrasib, which specifically target the G12C mutation. Clinical trials have shown promising results, offering new hope for patients with KRAS-mutant cancers.
